This presentation includes approach to a patient admitting with calcium channel or beta blocker overdose. Toxic mechanism and clinical features are explained. Management is subdivided to Resuscitation, Risk assessment, supportive care & monitoring, investigations, decontamination, antidote and disposition. Antidotes explained are HEIT therapy, vasopressors, glucagon and lipid emulsion
8. SUPPORTIVE CARE & MONITORING
◦ Invasive monitoring
◦ Atropine 0.6mg IV repeat up to 1.8 mg
◦ Often ineffective
◦ Calcium- Temporary measure to increase HR & BP
◦ Calcium gluconate 10% 60 ml or (0.6-1 ml/kg in children)
◦ calcium chloride 10% 20 ml IV over 15 min (0.2 ml/kg in children)
◦ Repeat boluses up to 3 times
◦ Consider infusion to keep Ca >2 mEq/L
◦ Ionised Ca every 30 min after & 1-2 hours
◦ Sodium bicarbonate for severe metabolic acidosis
◦ 50-100 mEq (0.5-1 mEq/kg in children)
9. INVESTIGATIONS
Bedside
◦ ECG- sinus bradycardia, varying degrees of AV block & slowing of intraventricular conduction, junctional &
ventricular escape rhythm
◦ ABG- lactatic acidosis+ high anion gap+low HCO3
◦ Blood sugar (hyperglycemia is a marker of severity)
Laboratory
◦ Serum Ca
◦ SE- hypokalemia
◦ S Creatinine
Imaging
◦ CXR- Pulmonary edema
◦ Echo- impaired contractility
10. DECONTAMINATION
◦ Gastric lavage- with in 1 hour
◦ Activated charcoal
◦ if <1 hr – for standard release or
◦ <4hr- for SR preparations
◦ Whole bowel irrigation if
◦ Patient is cooperative
◦ Present with in 4 hrs of ingestion of >10 tabs of Verapamil or Diltiazem SR
◦ No evidence of established toxicity
11. ANTIDOTE
◦ High dose insulin-euglycemic
therapy HEIT
◦ Vasoactive infusions
◦ IV lipid emulsion
◦ Cardiac pacing
◦ Circulatory support devices
12. ADRENERGIC AGENTS
◦ Agent with both alpha & beta agonist activity is useful
◦ Epinephrine or Norepinephrine- titrate to MAP 65mmHg
◦ But can use dopamine, vasopressin, dobutamine or isoproterenol as well
◦ When standard doses are inadequate, it is reasonable to use high doses or
multiple agents titrated to achieve a MAP >65 mmHg
◦ Consider Methylene blue if refractory vasoplegic
◦ Decrease cGMP formation
◦ Scavenge nitric oxide
◦ Inhibit nitric oxide synthesis- vasoconstriction
13. HEIT THERAPY
◦ Commence
◦ Glucose 25 g (50% 50 mL) IV bolus (if RBS <200 mg/dL)
◦ Short acting insulin 1 U/kg bolus to maximally saturate insulin receptors
◦ Continue
◦ Short acting insulin 0.5IU/kg/h & titrate every 30 min to a max 5 IU/kg/hr
◦ Dextrose 25g/h infusion titrated to maintain euglycemia (100-200mg/dL)
◦ Monitor
◦ Glucose- every 20 min for 1st hour, then every 1 h
◦ Potassium- replace only if <2.5 mmol/L & there is a source of potassium loss
14. Therapeutic end points
◦ Improvement in myocardial ejection fraction (>50%) increased BP (
SBP >90 mmHg in adults)
◦ Adequate heart rate (>60 bpm)
◦ Resolution of acidemia, euglycemia, adequate UOP (1-2 ml/kg/h)
◦ Reversal of cardiac conduction abnormalities (QRS interval <120 ms)
◦ Improved mentation
◦ Therapy is weaned off after withdrawal of other vasopressors, as
cardiotoxicity resolves.
15. GLUCAGON
◦ Bypass the beta receptor and stimulate cardiac activity via activation
of adenylate cyclase
◦ IV bolus 5mg in adult and 0.03 mg/kg in children given over 1-2 min
◦ A response is usually seen with in 15 min
◦ If no response – repeat a bolus
◦ If there is a hemodynamic improvement- maintenance infusion
5mg/kg/hr in adult 0.05 mg/kg/hr in children
16. IV LIPID EMULSION THERAPY
◦Create a pharmacological sink for fat soluble drugs, provide
fatty acid substrate for cardiac energy supply and improve
myocyte function by increasing intracellular calcium levels.
◦20% lipid emulsion 1.5ml/kg bolus over 2-3 minutes
followed by a 0.25 ml/Kg per min infusion
◦Can increase dose if blood pressure remain low
◦Upper limit- 10ml/kg over the initial 30 min
17. DISPOSITION
◦Clinical features – needs HDU/ICU care
◦Asymptomatic
◦ Cardiac monitoring for
◦ 4 hrs if standard release verapamil or Diltiazem
◦ 16 hrs if SR verapamil or Diltiazem
◦ Psychiatric assessment if possible
28. REFERENCES
◦ Tintinali Emergency Medicine- 9th Edition
◦ Life in the fast lane
◦ Murray L et al. Toxicology Handbook 3rd Edition. Elsevier Australia 2015. ISBN 9780729542241